专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090022727A1 INJECTABLE, NONAQUEOUS SUSPENSION WITH HIGH CONCENTRATION OF THERAPEUTIC AGENT 审中-公开
标题翻译：注意事项，治疗药物浓度高的非标准悬浮液
公开(公告)号：US20090022727A1
公开(公告)日：2009-01-22
申请号：US12020372
申请日：2008-01-25
申请人： Paul R. Houston , Guohua Chen , Andrew Sheung-King Luk
发明人： Paul R. Houston , Guohua Chen , Andrew Sheung-King Luk
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K47/44 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/19 , A61K38/385 , A61K38/47 , A61K39/3955 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/34 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/94 , C12Y302/01017
摘要： An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.
摘要翻译：包含悬浮在单一成分载体中的至少一种治疗剂的可注射非水悬浮液。单组分载体是单个两亲性材料，例如聚乙氧基化蓖麻油或其衍生物，聚氧乙烯烷基醚，聚氧乙烯山梨糖醇酐脂肪酸酯，聚氧乙烯硬脂酸酯，聚环氧乙烷 - 聚环氧丙烷 - 聚环氧乙烷的嵌段共聚物，聚氧化丙烯 - 聚环氧乙烷 - 聚环氧丙烷的嵌段共聚物，聚氧化乙烯 - 聚氧化丙烯的四官能嵌段共聚物，或聚氧化丙烯 - 聚环氧乙烷的四官能性嵌段共聚物。还公开了包含可注射的非水悬浮液的剂量试剂盒和施用可注射的非水悬浮液的方法。

2. 发明申请

US20120100149A1 Injectable, Non-Aqueous Suspension with High Concentration of Therapeutic Agent 有权
标题翻译：注射剂，高浓度治疗剂的非水性悬浮液
公开(公告)号：US20120100149A1
公开(公告)日：2012-04-26
申请号：US13282416
申请日：2011-10-26
申请人： Paul R. Houston , Guohua Chen , Andrew Sheung-King Luk
发明人： Paul R. Houston , Guohua Chen , Andrew Sheung-King Luk
IPC分类号： A61K39/395 , A61K47/34 , A61K31/7088 , A61K38/02 , A61K31/7052
CPC分类号： A61K47/44 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/19 , A61K38/385 , A61K38/47 , A61K39/3955 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/34 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/94 , C12Y302/01017
摘要： An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.
摘要翻译：包含悬浮在单一成分载体中的至少一种治疗剂的可注射非水悬浮液。单组分载体是单个两亲性材料，例如聚乙氧基化蓖麻油或其衍生物，聚氧乙烯烷基醚，聚氧乙烯山梨糖醇酐脂肪酸酯，聚氧乙烯硬脂酸酯，聚环氧乙烷 - 聚环氧丙烷 - 聚环氧乙烷的嵌段共聚物，聚氧化丙烯 - 聚环氧乙烷 - 聚环氧丙烷的嵌段共聚物，聚氧化乙烯 - 聚氧化丙烯的四官能嵌段共聚物，或聚氧化丙烯 - 聚环氧乙烷的四官能嵌段共聚物。还公开了包含可注射的非水悬浮液的剂量试剂盒和施用可注射的非水悬浮液的方法。

3. 发明申请

US20090074831A1 LOCAL VASCULAR DELIVERY OF mTOR INHIBITORS IN COMBINATION WITH PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR STIMULATORS 审中-公开
标题翻译：与过氧化物酶体增殖物激活受体刺激物组合的mTOR抑制剂的局部血管输送
公开(公告)号：US20090074831A1
公开(公告)日：2009-03-19
申请号：US11857285
申请日：2007-09-18
申请人： Robert Falotico , Andrew Sheung-King Luk , Theodore L. Parker , Jonathon Z. Zhao , Lei Zhao
发明人： Robert Falotico , Andrew Sheung-King Luk , Theodore L. Parker , Jonathon Z. Zhao , Lei Zhao
IPC分类号： A61K9/00 , A61K31/427 , A61K31/4439
CPC分类号： A61L31/16 , A61L31/10 , A61L2300/416 , A61L2300/432 , A61L2300/45 , A61L2300/602
摘要： Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the prevention of thrombosis. The drugs, agents, and/or compounds may also be utilized to treat specific disorders, including vulnerable plaque, and atherosclerosis in type 2 diabetic patients. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
摘要翻译：可以涂覆医疗装置，特别是可植入医疗装置，以最小化或基本上消除生物体对将生物体引入医疗装置的反应。医疗装置可以涂覆任何数量的生物相容性材料。治疗药物，药剂或化合物可以与生物相容性材料混合并固定在医疗装置的至少一部分上。这些治疗剂或化合物还可以进一步减少生物体对将生物体引入医疗装置的反应。此外，这些治疗药物，药剂和/或化合物可用于促进愈合，包括预防血栓形成。药物，药剂和/或化合物也可用于治疗2型糖尿病患者中的特定疾病，包括易损斑块和动脉粥样硬化。治疗剂也可以递送到疾病部位的区域。在区域递送中，液体制剂可能是期望的，以增加特定药物的功效和递送能力。此外，可以修改装置以促进内皮化。可以使用各种材料和涂覆方法来将药剂或化合物维持在医疗装置上，直到被输送和定位。此外，可以修改用于递送可植入医疗装置的装置，以减少在展开期间损害可植入医疗装置的可能性。此外，可以使用各种聚合物组合来控制来自可植入医疗装置的治疗药物，药剂和/或化合物的洗脱速率。

4. 发明授权

US08802095B2 Injectable, non-aqueous suspension with high concentration of therapeutic agent 有权
标题翻译：注射剂，高浓度治疗剂的非水性悬浮液
公开(公告)号：US08802095B2
公开(公告)日：2014-08-12
申请号：US13282416
申请日：2011-10-26
申请人： Paul R. Houston , Guohua Chen , Andrew Sheung-King Luk
发明人： Paul R. Houston , Guohua Chen , Andrew Sheung-King Luk
IPC分类号： A61K39/395
CPC分类号： A61K47/44 , A61K9/0019 , A61K9/08 , A61K9/10 , A61K9/19 , A61K38/385 , A61K38/47 , A61K39/3955 , A61K47/10 , A61K47/14 , A61K47/26 , A61K47/34 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/31 , C07K2317/94 , C12Y302/01017
摘要： An injectable, nonaqueous suspension including at least one therapeutic agent suspended in a single component vehicle. The single component vehicle is a single amphiphilic material, such as a polyethoxylated castor oil or derivative thereof, a polyoxyethylene alkyl ether, a polyoxyethylene sorbitan fatty acid ester, a polyoxyethylene stearate, a block copolymer of polyethylene oxide-polypropylene oxide-polyethylene oxide, a block copolymer of polypropylene oxide-polyethylene oxide-polypropylene oxide, a tetra-functional block copolymer of polyethylene oxide-polypropylene oxide, or a tetra-functional block copolymer of polypropylene oxide-polyethylene oxide. A dosage kit that includes the injectable, nonaqueous suspension and a method of administering the injectable, nonaqueous suspension are also disclosed.
摘要翻译：包含悬浮在单一成分载体中的至少一种治疗剂的可注射非水悬浮液。单组分载体是单个两亲性材料，例如聚乙氧基化蓖麻油或其衍生物，聚氧乙烯烷基醚，聚氧乙烯山梨糖醇酐脂肪酸酯，聚氧乙烯硬脂酸酯，聚环氧乙烷 - 聚环氧丙烷 - 聚环氧乙烷的嵌段共聚物，聚氧化丙烯 - 聚环氧乙烷 - 聚环氧丙烷的嵌段共聚物，聚氧化乙烯 - 聚氧化丙烯的四官能嵌段共聚物，或聚氧化丙烯 - 聚环氧乙烷的四官能嵌段共聚物。还公开了包含可注射的非水悬浮液的剂量试剂盒和施用可注射的非水悬浮液的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式